Radnor Capital Management LLC Acquires New Shares in Edwards Lifesciences Co. (NYSE:EW)

Radnor Capital Management LLC acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 5,784 shares of the medical research company’s stock, valued at approximately $546,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Castleview Partners LLC bought a new stake in shares of Edwards Lifesciences in the first quarter worth about $25,000. Core Alternative Capital boosted its position in shares of Edwards Lifesciences by 96.1% during the first quarter. Core Alternative Capital now owns 353 shares of the medical research company’s stock worth $29,000 after buying an additional 173 shares during the period. Compass Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth about $31,000. Jones Financial Companies Lllp acquired a new position in shares of Edwards Lifesciences during the first quarter worth about $33,000. Finally, MCF Advisors LLC boosted its position in shares of Edwards Lifesciences by 179.6% during the first quarter. MCF Advisors LLC now owns 411 shares of the medical research company’s stock worth $34,000 after buying an additional 264 shares during the period. Institutional investors own 79.25% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the company’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $76.69, for a total value of $115,035.00. Following the sale, the vice president now owns 23,950 shares in the company, valued at approximately $1,836,725.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, VP Daveen Chopra sold 1,500 shares of the company’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $76.69, for a total transaction of $115,035.00. Following the sale, the vice president now owns 23,950 shares in the company, valued at approximately $1,836,725.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Catherine M. Szyman sold 5,000 shares of the company’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $90.52, for a total value of $452,600.00. Following the sale, the vice president now owns 34,814 shares in the company, valued at approximately $3,151,363.28. The disclosure for this sale can be found here. Insiders have sold 174,359 shares of company stock worth $14,301,522 in the last 90 days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded down $0.56 during trading on Friday, reaching $73.46. 730,739 shares of the company’s stock were exchanged, compared to its average volume of 3,146,977. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.30 and a current ratio of 3.15. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $94.87. The company has a market cap of $44.66 billion, a P/E ratio of 32.78, a PEG ratio of 3.95 and a beta of 1.03. The firm’s 50-day moving average price is $81.72 and its 200 day moving average price is $83.95.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.51 billion. Edwards Lifesciences had a return on equity of 25.43% and a net margin of 24.56%. Edwards Lifesciences’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.63 EPS. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Piper Sandler reduced their price objective on Edwards Lifesciences from $88.00 to $83.00 and set a “neutral” rating for the company in a research report on Friday, September 8th. Jefferies Financial Group increased their price target on Edwards Lifesciences from $103.00 to $107.00 and gave the company a “buy” rating in a research report on Tuesday, July 25th. 58.com reissued a “reiterates” rating on shares of Edwards Lifesciences in a research report on Tuesday, June 27th. Royal Bank of Canada reissued an “outperform” rating and set a $96.00 price target on shares of Edwards Lifesciences in a research report on Thursday, August 17th. Finally, Citigroup increased their price target on Edwards Lifesciences from $101.00 to $110.00 in a research report on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $92.42.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.